Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease
Table 2
Genotype and allele frequencies in different psoriatic disease groups and controls.
Controls, N = 550
Total PD, N = 690
PsA, N = 187
PCP, N = 309
value, OR (95% CI)
NFKB1 rs230526 A/G
AA vs. AG + GG
AA
77 (0.14)
108 (0.16)
30 (0.16)
42 (0.14)
AG
264 (0.48)
359 (0.52)
95 (0.51)
164 (0.53)
OR = 1.21
GG
209 (0.38)
223 (0.32)
62 (0.33)
103 (0.33)
0.73–2.02
NFKBIA rs7152376 T/C
CC + CT vs. TT
TT
231 (0.42)
291 (0.42)
64 (0.34)
147 (0.48)
TC
242 (0.44)
314 (0.46)
89 (0.48)
133 (0.43)
OR = 1.74
CC
77 (0.14)
85 (0.12)
34 (0.18)
29 (0.09)
1.20–2.54
NFKBIZ rs3217713 indel
Del/Del vs. Ins/Ins + Ins/Del
INS/INS
336 (0.61)
451 (0.65)
124 (0.66)
210 (0.68)
INS/DEL
193 (80.35)
207 (0.30)
51 (0.27)
90 (0.29)
OR = 2.29
DEL/DEL
21 (0.04)
32 (0.05)
12 (0.06)
9 (0.03)
0.94–5.53
and OR values correspond to the putative PsA risk vs. non‐risk genotypes. PD: psoriatic disease; PsA: psoriatic arthritis; PCP: pure cutaneous psoriasis (absence of arthritis after 10 or more years of psoriasis onset); OR: odds ratio; CI: confidence interval.
